Ultragenyx and Kyowa Kirin announce Health Canada approval of Crysvita™ (burosumab)
Ultragenyx and Kyowa Hakko Kirin announced that Crysvita™ (burosumab injection) has been approved by Health Canada for treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older. XLH is a rare, hereditary, lifelong disease. December 06, 2018
